Back to Main

Faculty Detail    
Name SELVARANGAN PONNAZHAGAN
 
Campus Address SHEL 814 Zip 2182
Phone 205-934-6731
E-mail pons@uab.edu
Other websites
     


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Pathology   Molecular & Cellular Pathology Professor
Center  Arthritis & Musculoskeletal Diseases Center  Arthritis & Musculoskeletal Diseases Center Professor
Center  Biomedical Engineering  Biomatrix Eng Regen Med (BERM) Ctr Professor
Center  Center for Biophysical Sciences/Engineering  Center for Biophysical Sciences/Engineering Professor
Center  Center for Metabolic Bone Disease  Center for Metabolic Bone Disease Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  Cystic Fibrosis Research Center  Cystic Fibrosis Research Center Professor
Center  General Clinical Research Center  Nephrology Research & Training Center Professor

Graduate Biomedical Sciences Affiliations
Cancer Biology 
Cell, Molecular, & Developmental Biology 
Integrative Biomedical Sciences 
Medical Scientist Training Program 
Molecular and Cellular Pathology Program 
Pathobiology and Molecular Medicine 

Biographical Sketch 
Dr. Ponnazhagan received his BS and MS degrees from the University of Madras and his PhD degree in Genetics from the University of Madras. He completed postdoctoral training at the Indiana University School of Medicine, Indianapolis.

Society Memberships
Organization Name Position Held Org Link
American Association for Cancer Research     
American Association for the Advancement of Science     
American Society for Gene Therapy     
American Society for Microbiology     

Research/Clinical Interest
Title
Adeno-associated virus gene therapy
Description
The major research interest of my lab is biology and experimental therapeutics of cancer and bone diseases. I have been working in cancer immunology, osteopenia and cancer bone metastasis for over 10 years and published several papers in these fields. With combined experience in these three inter-related fields, we are currently expanding our research efforts to understand the immune mechanisms of osteolytic cancer metastasis and develop novel treatment methods and test them first in preclinical animal models. Using gene transfer apporaches, our studies focus on anti-angiogenic gene therapy for solid tumors, dendritic cell-based vaccines for cancer immunotherapy, and genetically-engineered stem cell therapy for bone defects. In addition, the lab is also focused on basic biology of adeno-associated virus (AAV) and AAV vector modifications to achieve high-efficiency gene transfer and targeting.

Selected Publications 
Publication PUBMEDID
Yang, SW, Cody JJ, Rivera, AA, Waehler, R, Wang, M, Kimball, KJ, Alvarez RA, Siegal, GP, Douglas, JT, and Ponnazhagan, S. Conditionally-Replicating Adenovirus Expressing TIMP2 for Ovarian Cancer Therapy. Clin. Cancer Res. 2011, 17:538-549.  21115652 
Hensel JA, Chanda D, Kumar S, Sawant, A., and Ponnazhagan S. LL-37 as a therapeutic target for late stage prostate cancer. Prostate 2011 May;71(6):659-70.   20957672 
Triozzi PL, Aldrich W, Ponnazhagan S. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists. Vaccine. 2010, 28:7837-7843.  20937315 
Kumar, S., Nagy T., and Ponnazhagan, S. Therapeutic potential of genetically modified adult stem cells for osteopenia. Gene Therapy 2010, 17:105-116.   20068549 
Chanda D, Isayeva T, Kumar S, Hensel JA, Sawant A, Ramaswamy G, Siegal GP, and Ponnazhagan, S. Therapeutic potential of adult stem cells for osteolytic bone metastasis. Clin. Cancer Res. 2009, 15:7175-85  19920103 
Isayeva., T., Moore, L.D., Chanda, D., Chen, D., and Ponnazhagan, S. Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status. Prostate 2009,69:1055-66.   19301304 
Moore, L.D, Isayeva, T., Siegal, G.P., and Ponnazhagan, S. Silencing of TGF-β1 in situ by RNA interference for breast cancer: Implications for proliferation and migration in vitro and metastasis in vivo. Clin. Cancer Res. 2008, 14: 4961-4970  18676771 
Ren, C., Kumar S., Diptiman C., and Ponnazhagan, S. Therapeutic potential of mesenchymal stem cells producing IFN-α in a mouse melanoma lung metastasis model. Stem Cells 2008, 9:2332-2338.   18617688 
Chanda D, Isayeva T, Kumar S, Siegal GP, Szafran AA, Zinn KR, Reddy VV, Ponnazhagan S. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol Ther. 2008 May;16(5):871-8. 18388919   18388919  
Kumar S, Ponnazhagan S. Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression.FASEB J. 2007 Dec;21(14):3917-27.  17622670  
Isayeva, I., Chanda, D., Eltoum, I-E., and Ponnazhagan, S. Effects of sustained anti-angiogenic therapy in multi-stage prostate cancer in TRAMP mice. Cancer Res. 2007 Jun 15;67(12):5789-97.  17575146  
Pereboeva, L., Komarova, S., Roth, J., Ponnazhagan, S., and Curiel D.T. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus. Gene Ther.2007 Apr;14(8):627-37  17251987 
Ren, C.., White, A.F. and Ponnazhagan, S. Notch-1 augments intracellular trafficking of adeno-associated virus 2. J. Virol. 2007, 81:2069-2073.  17151095 
White, A.F. and Ponnazhagan, S. Airway epithelium directed gene therapy for cystic fibrosis. Med. Chem. 2006, 2: 499-503.  17017989 
Isayeve, T., Ren, C., and Ponnazhangan, S. Intraperitoneal transduction of adeno-associated virus 2 expressing angiostatin and endostatin synergistically augments paclitaxel therapy and tumor-free survival in a mouse model of epithelial ovarian cancer. Gene. Ther. 2007, 14:138-146.  16943851 
Fukuchi, K., Taharaa, K., Kima, H-D., Maxwella, J.A., Lewisb, T.L., Accavitti-Loperb, M.A., Kim, H., Ponnazhagan, S., Lalonde, R. Anti-Aß single chain antibody delivery via adeno-associated virus for treatment of Alzheimer’s disease. Neurobiol. Dis. 2006, 23: 502-511.  16766200 
Sorscher, EJ, Harris, J., Alexander, M., Rottgers, A., Hardy, K., Ponnazhagan, S., Collawn, J.F., McClintock, J. Amsler, C.D., Webster, A., Maddry, J., Baker, B.J., Hong, J.S. Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screening. Gene Therapy 2006, 13:781-788.  16307002 
Batchu, R.B., Moreno, A.M., Szmania, S.M., Bennett, G., Spagnoli, G.C., Ponnazhagan, S., Barlogie, B., Tricot, G.T., and van Rhee, F. Protein transduction of dendritic cells for NY-ESO-1 based immunotherapy of myeloma. Cancer Res. 2005, 65: 10041-10049.  16267030 
Kumar, S., Mahendra, G., and Ponnazhagan, S. Determination of osteoprogenitor-specific promoter activity in murine mesenchymal stem cells by recombinant adeno-associated virus transduction. Biochim et Biophys. Acta 2005, 1731: 95-103.  16225939 
Ren, C., Kumar, S., Shaw, D.R. and Ponnazhagan, S. Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo. Human Gene Therapy. 2005 Sep;16(9):1047-57.  16149903 
Aldrich, W.A, Ren, C, White, A.F., Zhou, S-Z, Kumar, S., Jenkins, C.B., Shaw, D.R., Strong, T.V., Triozzi, P.L., and Ponnazhagan, S. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands. Gene Therapy 2006, 13: 29-39.  16136165 
Isayeva, T., Ren, C., and Ponnazhagan, S. Recombinant adeno-associated virus 2 -mediated anti-angiogenic prevention in a mouse model of intraperitoneal ovarian cancer. Clin. Cancer Res. 2005, 11:1342-1347.  15709207 
Kumar, S., Mahendra, G., Nagy, T.R., and Ponnazhagan, S. Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and establishment of an immunocompetent murine model for ex vivo osteoporosis gene therapy. Hum. Gene Ther. 2004, 15: 1196-1207.  15684696 
Kumar, S., and Ponnazhangan, S. Gene Therapy for osteoinduction. Curr. Gene Ther. 2004, 4: 287-296.  15384942 
Mahendra, G., Mahasreshti, P., Curiel, D.T., Stockardt, R., Grizzle, W.E., Alapati, V., Singh, R., Siegal, G.P., and Ponnazhagan, S. Anti-angiogenic gene therapy through adeno-associated virus 2-mediated stable expression of soluble Flt-1 receptor Cancer Gene Ther. 2005, 12: 26-34.  15359287 
Ponnazhagan, S., Mahendra, G., Lima, J., Aldrich, W., Jenkins, C., Ren, C., Kallman, L., Strong, T., Shaw, D., and Triozzi, P. Augmentation of anti-tumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvants Hum. Gene Ther. 2004, 15: 856-864.  15353040 
Isayeva, T., and Ponnazhagan, S. Anti-angiogenic gene therapy for cancer. Int. J. Oncol. 2004, 25: 335-343.  15254730 
Ponnazhagan, S. Mahendra, G., Kumar, S., Shaw, D., Meleth, S., Stockardt, R., and Grizzle, W.E. Adeno-associated virus-2-mediated anti-angiogenic gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res. 2004, 64: 1781-1787.  14996740 
Ponnazhagan, S. Parvovirus vectors for cancer gene therapy Exp. Opin. Biol.Ther. 2004, 4: 53-64.  14680468  
Ponnazhagan, S., Mahendra, G., Kumar, S., Thompson, J.A., and Casillas Jr., M. Targeting of recombinant adeno-associated virus-2 through an avidin-linked ligand. J. Virol., 2002, 76: 12900-12907.  12438615  
Ponnazhagan, S. Adeno-associated virus vectors for genetic immunization. J. Immunol. Res. 2002, 26, 1-3: 247-253.  12403362  
Ponnazhagan, S., Curiel D.T., Shaw, D.R., Alvarez, R., and Siegal, G.P. Adeno-associated virus for cancer gene therapy. Cancer Res. 2001, 61:6313-6321.
 
11522617 
Ponnazhagan, S. Ponnazhagan, S. Adeno-associated virus in Viral Therapy of Cancer Ed: Harington K.J., Panda, H.S., and Vile, R.G. John Wiley & Sons, Ltd. 2006 (in press).
Ed: Harington K.J., Panda, H.S., and Vile, R.G. John Wiley & Sons, Ltd. 2006 (in press).